EVI5: Potential Drug Target Or Biomarker (G7813)

Target Name: EVI5

NCBI ID: G7813

EVI5

EVI5: Potential Drug Target Or Biomarker

EVI5 (Ecotropic viral integration site 5 protein homolog (isoform 2)) is a protein that is expressed in various tissues and organs, including the brain, heart, liver, and muscle. Its function is not well understood, but it is known to play a role in the integration of viral DNA into the host cell genome. This protein has also been implicated in the development and progression of certain diseases, which has led to its potential as a drug target or biomarker.

Diseases associated with EVI5

One of the diseases associated with EVI5 is neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. These conditions are characterized by the progressive loss of brain cells and progressive decline in cognitive and motor function. It is thought that EVI5 may be involved in the development and progression of these diseases by contributing to the disruption of normal cellular processes that are necessary for brain function.

Another disease associated with EVI5 is cancer. Many viruses, including human herpesvirus 8 (HHV-8), have been shown to contribute to the development and progression of cancer. EVI5 has been shown to be expressed in various types of cancer, including liver, lung, and cervical cancer. This suggests that EVI5 may be involved in the development and progression of cancer by contributing to the integration of viral DNA into the host cell genome.

EVI5 as a drug target

EVI5 has been shown to play a role in the development and progression of several diseases, which has led to its potential as a drug target. One potential approach to targeting EVI5 is to use small molecules that can inhibit its function. This could be done by identifying molecules that interact with EVI5 and preventing it from participating in the integration of viral DNA into the host cell genome.

Another potential approach to targeting EVI5 is to use antibodies that recognize and target specific regions of the protein. This could be done by identifying antibodies that recognize a specific epitope (a region of the protein that is unique from one isoform to another) on EVI5 and using them to block its function.

EVI5 as a biomarker

In addition to its potential as a drug target, EVI5 may also be used as a biomarker for certain diseases. For example, EVI5 has been shown to be expressed in the brains of individuals with Alzheimer's disease, which suggests that it may be a useful biomarker for this condition. Similarly, EVI5 has been shown to be expressed in the livers of individuals with liver cancer, which suggests that it may be a useful biomarker for this condition.

Conclusion

EVI5 is a protein that is expressed in various tissues and organs and is involved in the integration of viral DNA into the host cell genome. Its function is not well understood, but it is known to play a role in the development and progression of several diseases, including neurodegenerative diseases and cancer. As a result, EVI5 has the potential as a drug target or biomarker. Further research is needed to fully understand its function and to develop effective treatments for the diseases associated with it.

Protein Name: Ecotropic Viral Integration Site 5

Functions: Functions as a regulator of cell cycle progression by stabilizing the FBXO5 protein and promoting cyclin-A accumulation during interphase. May play a role in cytokinesis

The "EVI5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EVI5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets